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Abstract
Background:  Therapy with 3-Hydroxy-3-methylglutaryl Co-enzyme A reductase inhibitors
(statins) improve outcomes in a broad spectrum of patients with hyperlipidemia. However,
effective therapy requires ongoing medication adherence; restrictive pharmacy policies may
represent a barrier to successful adherence, particularly among vulnerable patients. In this study
we sought to assess the relationship between the quantity of statin dispensed by the pharmacy with
patient adherence and total cholesterol.
Methods: We analyzed a cohort of 3,386 patients receiving more than one fill of statin medications
through an integrated, inner-city health care system between January 1, 2000 and December 31,
2002. Our measure of adherence was days of drug acquisition divided by days in the study for each
patient, with adequate adherence defined as ≥ 80%. Log-binomial regression was used to determine
the relative risk of various factors, including prescription size, on adherence. We also assessed the
relationship between adherence and total cholesterol using multiple linear regression.
Results: After controlling for age, gender, race, co-payment, comorbidities, and insurance status,
patients who obtained a majority of fills as 60-day supply compared with 30-day supply were more
likely to be adherent to their statin medications (RR 1.41, 95% CI 1.28–1.55, P < 0.01). We found
that statin non-adherence less than 80% was predictive of higher total serum cholesterol by 17.23
± 1.64 mg/dL (0.45 ± 0.04 mmol/L).
Conclusion: In a healthcare system serving predominantly indigent patients, the provision of a
greater quantity of statin medication at each prescription fill contributes to improved adherence
and greater drug effectiveness.
Background
Adherence to medications such as statins is a critical com-
ponent in the treatment of chronic illness. Adherence can
be defined as the extent to which patients follow the
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instructions that they are given for prescribed treatments
[1]. Although many patient and provider factors promote
successful adherence, these are often difficult to modify.
By contrast, barriers to adherence in the delivery system
itself are more easily addressed [2].
Pharmacy policy is a critical step in modulating medica-
tion adherence behavior, especially in health care systems
that provide incentives to fill medications within the sys-
tem. In such systems, pharmacy records provide a means
to ascertain the pattern and timing of drug acquisition, as
well as providing information on related factors, such as
co-payment and prescription fill size. Refill adherence is
associated with improvements in health outcomes among
patients with hypertension and coronary heart disease
[3,4]. Conversely, approximately 10% of all hospital
admissions are attributable to a patient's inability to fol-
low advice regarding their drug therapy plan [5]. Phar-
macy policies, such as increasing the amount of co-
payment or reducing the size of prescription pills, are
designed to reduce pharmacy costs by increasing patient
cost-sharing or reducing waste. However, these strategies
may not lower overall costs if accompanied by a decrease
in drug adherence [6,7]. Few studies have directly evalu-
ated the effect of prescription size on adherence [8]; intu-
itively it seems that an increase in the amount of
medication dispensed could positively influence patients'
ongoing medication adherence and reduce total phar-
macy costs by reducing dispensing services.
Because system issues such as pharmacy and reimburse-
ment policies can impact adherence behavior, we sought
to determine the effect of prescription size on patients'
adherence to hyperlipidemia therapy. As a drug class 3-
Hydroxy-3-methylglutaryl Co-enzyme A reductase inhibi-
tors (statins) are ideally suited for the assessment of
adherence. They are taken once daily, administered indef-
initely, and are associated with a reduction in CHD events
in both primary and secondary prevention settings [9].
The effectiveness of statins is easily gauged by measuring
cholesterol levels. To determine whether a 60-day statin
dispensing policy also influenced clinical outcomes, we
also assessed the effect of prescription size on cholesterol
levels in patients undergoing treatment for hyperlipi-
demia. We hypothesized that a larger dispensed prescrip-
tion size would be associated with greater drug adherence
and decreased total cholesterol levels, even after control-
ling for baseline clinical and sociodemographic character-
istics.
Methods
This retrospective cohort study examined patients receiv-
ing care and medications at Denver Health Medical
Center (DHMC) over a three-year period. DHMC is a pub-
lic safety net hospital serving a predominantly minority
and indigent population, which provides nearly one third
of the uncompensated medical care for the state of Colo-
rado. Denver Health (DH) is an integrated health care sys-
tem including community health clinics, subspecialty care
clinics, and an acute care hospital (DHMC). Outpatient
clinics and inpatient services are served by a single inte-
grated pharmacy system. DH actively screens patients for
enrollment in an indigent care prescription program,
which provides discounted drug benefits to eligible
patients. Although this is not an insurance benefit, it does
allow patients to obtain their medications for free or a
small co-payment. In addition, the pharmacy participates
in many medication assistance programs that provide
medications to qualifying persons free of charge.
Patients were eligible for study inclusion if they had
received at least two prescriptions for any statin between
January 1, 2000 and December 31, 2002. Each patient's
study period was defined from the day of his or her first
statin medication fill until the day of his or her last statin
prescription fill. Thus, the number of days in the study for
each patient varied, and our investigation was not limited
to patients newly initiated on statin therapy. Study
patients' records were linked to laboratory data through
each patient's unique medical record number. The Colo-




Our indirect measure of adherence was pharmacy refills,
given that patients seen in Denver Health had a substan-
tial financial incentive to fill their medications within the
system. In such closed pharmacy systems, pharmacy
records provide a virtually complete measure of medica-
tions obtained [10,11]. Each patient's adherence score
was calculated as their days of drug acquired divided by
their days in the study (days from first prescription fill to
last prescription fill), using the methodology of Steiner et
al [10]. High adherence was defined by an adherence
score of greater or equal to 80% and non-adherent as an
adherence score of less than 80%. This cut point is con-
ventional in the adherence literature [12-14] and yields
measures of association that are easily interpreted. Ade-
quate treatment of hyperlipidemia does not require per-
fect medication adherence, making the 80% cut off an
appropriate maker for adherence.
Achievement of target cholesterol levels
Serum cholesterol data was obtained from Denver Health
laboratory records. The cholesterol level analyzed was the
last available cholesterol value obtained during or not
more than 6 months after the patient's study period.BMC Health Services Research 2007, 7:175 http://www.biomedcentral.com/1472-6963/7/175
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Independent variables
Days supply
The main independent variable of interest was days sup-
ply of statin received at each prescription fill. The amount
of statin medication per fill dispensed at our institution
during the study period was usually either a 30- or 60-day
supply of medication. At the time of this study, a provider
could write for up to a 60 day supply of medication and
the patient would be charged a single co-payment for that
fill. Patients were grouped into either the 30- or 60-day
category based on whether the modal size of their pre-
scriptions was less than 45 (30 day) or greater than or
equal to 45 (60 day).
Sociodemographic and clinical variables
Age was defined as the patient's age at the midpoint of the
study period. Insurance status was defined as the method
most frequently utilized by the patient. Co-payment was
measured for each prescription fill. The co-payment
required for each patient and each prescription varied
with a patient's financial status and insurance status.
Patients were considered to have no co-pay during the
study if the median co-pay for all of their statin prescrip-
tions was equal to $0. Gender and self-defined race/eth-
nicity were also collected from pharmacy records. Overall
burden of chronic disease was controlled for by totaling
the number of comorbidities identified in the last 6
months from the patient's pharmacy records, using mod-
ified Chronic Disease Score methodology [15].
Statistical analysis
All analyses were performed using SAS statistical software
version 8.2 or higher (SAS Institute, Inc., Cary, NC). Two-
sided P values of less than or equal to 0.05 were consid-
ered statistically significant. Demographic variables were
compared between adherence groups using the chi-square
statistic for categorical variables and a two-sample t test
for continuous variables. Continuous variables are pre-
sented as means ± standard deviation (SD) and categori-
cal variables are presented as number (n) and percent per
group.
Log-binomial regression was utilized to determine the
relationship between days supply and adherence while
controlling for other factors. Additional independent var-
iables assessed in the log-binomial regression model
included gender, age, race/ethnicity, insurance status, co-
payment, and number of co morbidities. Because the
reporting of odds ratios for common outcomes may over-
estimate the magnitude of association, we used log-bino-
mial regression to directly calculate adjusted risk ratios
[16].
We assessed whether receiving a 30- or 60-day supply
more frequently had an effect on the patient's final serum
cholesterol level using a two-sample t-test. Multiple linear
regression was used to identify factors impacting the
patient's final cholesterol value. We modeled the data so
that the intercept predicted the cholesterol value for a 50
year old white male, insured with no co-payment, who
received mostly a 60-day supply of statin medication, and
who was adherent. We then ran a set of simplified the
models to calculate the indirect effect of statin adherence
on cholesterol level to explore whether days supply was a
strong mediator in the process.
A paired analysis comparing adherence was performed on
the subgroup of patients that received at least 2 consecu-
tive fills each of 30- and 60-day statin medication. An
adherence score was calculated for each of the longest
consecutive strings of 30- and 60-day supplies for each
patient and the scores were compared using a paired t test.
Results
We obtained data for 5,073 patients who had filled any
statin prescription during the study period. After exclud-
ing those who had filled only one statin prescription,
3,386 patients were available for analysis, encompassing
over 27,000 statin prescription fills. Total cholesterol val-
ues were available for 3,292 of these patients. Dichot-
omizing adherence at greater than or equal to 80%, 1,610
of the 3,386 (47.5%) patients were classified as adherent
with statin therapy. Adherent and non-adherent patients
are compared in Table 1. In univariate analysis neither
insurance status nor the obligation of a co-payment
showed a significant relationship to adherence. A higher
percent of patients in the adherent group received 60-day
statin fills compared to the non-adherent group (81.2%
vs. 70.2%, P < 0.001). Moreover, final serum cholesterol
levels were lower in the adherent patients (mean (std) =
176.8 (42.2) vs. 195.9 (50.8), P < 0.001).
Table 2 shows the adjusted risk ratios (RR) resulting from
the log-binomial regression model. Patients with mostly
60-day statin fills were more likely to achieve at least 80%
adherence than those who received mostly 30-day statin
fills (RR 1.41, 95% confidence interval (CI) 1.28–1.55).
Other factors significantly predicting adherence were
increasing age, additional comorbidities, gender, and
race. Insurance and co-payment were not significant pre-
dictors of adherence in this model. A paired comparison
of the 1,412 patients who had received both 30- and 60-
day fills demonstrated that when these individuals
received 60-day fills, their adherence was 82.9% ± 52%
compared to 73.9% ± 59% when receiving 30-day fills (P
< 0.001).
Patients in the 60-day supply group had a lower final
serum cholesterol value of 185.3 ± 46.2 mg/dL (4.80 ±
1.20 mmol/L) compared to 191.5 ± 52.6 mg/dL (4.96 ±BMC Health Services Research 2007, 7:175 http://www.biomedcentral.com/1472-6963/7/175
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1.36 mmol/L) for the 30-day supply group (P = 0.003).
Multiple linear regression showed that lower adherence to
statin medications was associated with an increase in final
serum cholesterol values of 17.23 ± 1.64 mg/dL (0.45 ±
0.04 mmol/L) over the value predicted for the intercept (P
< 0.001) (Table 3). Other significant predictors of final
cholesterol value included age, gender, and the combina-
tion of having a median co-payment of greater than $0
and being uninsured. After adjusting for statin adherence
demographics and copay, the effect of days supply on
final cholesterol value was no longer significant (P  =
0.09).
The average (s.d.) median co-payment for the 691
(20.4%) of the population with a non-zero median co-
payment was $15.69 ($19.74). The other 2695 (79.6%) of
the population filled at least half of their prescriptions at
no cost through our robust indigent care prescription
plan. In the population that was uninsured but did not
qualify for free drug (n = 346) cholesterol levels were
higher by 10 mg/dL than those who were uninsured but
did qualify for free drug.
Discussion
Our results demonstrate that patients receiving a larger
quantity of statin medication at each fill achieved greater
adherence, and that higher adherence was a significant
predictor of lower serum cholesterol. In addition, patients
who changed from a 30-day fill to a 60-day fill pattern had
higher rates of adherence with the larger supply. Given the
relationship of greater adherence with lower cholesterol
levels, this suggests that an institutional pharmacy strategy
of increasing the days supply of statins dispensed has the
potential to favorably impact modifiable cardiac risk fac-
tors among vulnerable patients with limited resources, by
facilitating adherence behavior. Since the major reason for
nonadherence cited by patients is forgetfulness [17] the
provision of a 60-day fill may facilitate the ability of
patients to follow a regular medical regimen. These find-
ings have important implications for other closed phar-
macy systems and countries with universal prescription
Table 1: Relationship between Patient Characteristics and Statin Adherence
Total (n = 3386) ≥ 80% adherence 
(n = 1610)
< 80% adherence 
(n = 1776)
P Value
Age (years), mean (SD) 57.8 (10.9) 58.7 (10.7) 57.0 (11.0) <0.001
Gender, n (%)
Female 1932 (57.1) 881 (54.7) 1051 (59.2) 0.009
Male 1454 (42.9) 729 (45.3) 725 (40.8)
Race, n (%)
Hispanic 1584 (46.8) 683 (42.4) 901 (50.7)
White 919 (27.1) 515 (32.0) 404 (22.8) <0.001
Black 638 (18.8) 276 (17.1) 362 (20.4)
Other 245 (7.2) 136 (8.5) 109 (6.1)
Insurance, n (%)
Insured 989 (29.2) 485 (30.1) 504 (28.4) 0.26
Uninsured 2397 (70.8) 1125 (69.9) 1272 (71.6)
No. of comorbidities, mean (SD) 4.3 (2.0) 4.5 (2.0) 4.1 (2.0) <0.001
Diabetics, n (%) 1687 (49.8) 781 (48.5) 906 (51.0) 0.15
$0 co-pay, n (%) 2695 (79.6) 1276 (79.3) 1419 (79.9) 0.64
Days in study, mean (SD) 571.6 (315.7) 546.2 (338.1) 594.6 (292.2) <0.001
No. of statin prescriptions, mean (SD) 8.0 (5.2) 9.5 (5.9) 6.6 (4.1) <0.001
Days supply, n (%)
30 day 833 (24.6) 303 (18.8) 530 (29.8) <0.001
60 day 2553 (75.4) 1307 (81.2) 1246 (70.2)
Cholesterol (mg/dl)*, mean (SD) 186.8 (47.9) (n = 3292) 176.8 (42.2) (n = 1573) 195.9 (50.8) (n = 1719) <0.001
Data are either n (%) per group with P Values determined from chi-squared tests or mean (standard deviation) with two sample t test P Values.
*Cholesterol values available on n = 3292 patients, multiply by 0.0259 to convert cholesterol to mmol/L.
Table 2: Multivariate Predictors of Statin Adherence
Adjusted Risk Ratio* 
(95% Confidence Interval)
60 versus 30 days supply 1.40 (1.27–1.55)
Age (per 10 year increase) 1.07 (1.03–1.10)
Female versus Male 0.92 (0.86–0.98)
Race (Black versus White) 0.77(0.70–0.86)
Race (Hispanic versus White) 0.77(0.72–0.84)
Race (Other versus White) 0.98 (0.86–1.10)
Each additional comorbidity 1.04 (1.03–1.06)
$0 Co-pay and uninsured 1.06 (0.97–1.17)
> $0 Co-pay and insured 1.12 (0.99–1.27)
> $0 Co-pay and uninsured 0.91(0.79–1.05)
*Log-Binomial Regression used to calculate adjusted risk ratiosBMC Health Services Research 2007, 7:175 http://www.biomedcentral.com/1472-6963/7/175
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drug coverage, where the costs associated with the loss of
co-payment may be offset by greater adherence and drug
efficacy as well as institutional efficiency.
There are several strengths to our study. First, we assessed
all patients within Denver Health who received multiple
statin prescriptions and received follow-up cholesterol
measurement. This assures that our results are broadly
applicable within that patient population. Second,
patients in our cohort were unaware that adherence
would be assessed, and thus adherence behavior was not
altered by adherence measurement, a common flaw of
studies based on self-report, electronic monitoring, or pill
counts. Most importantly, identifying systematic means of
improving adherence among vulnerable populations is
unique. Numerous studies have shown disparities in
guideline-based therapies among minorities and the poor
[18-21]. The provision of greater prescription quantity
therefore represents a potential method for improving
care in this population.
A significant fraction of patients with hyperlipidemia dis-
continue therapy within the first year [14] and never rein-
itiate therapy. Therefore our inclusion of patients during
the time that they were actually filling their statin would
indicate that we cannot generalize adherence rates from
this study to the entire population of individuals who
were intended to receive treatment. We excluded 33.3% or
1687 patients from analysis who only filled one statin pre-
scription during the study period. This is not unexpected
based on prior work that has shown that even in patients
with known coronary artery disease up to 60% discon-
tinue lipid-lowering medications in the first year [22].
Many similar studies have found a direct relationship
between co-payment size and adherence [23,24]. We did
not observe this relationship in our study. However, as
noted above, the majority of our patients had a median
co-payment of $0.
This study has a number of limitations. The use of medi-
cation acquisition to determine adherence likely overesti-
mates actual adherence because it assumes that patients
consume all of the medication for prescriptions that are
filled. We did not analyze low-density lipoprotein (LDL)
cholesterol levels because these data were not available for
many patients. Moreover, the National Cholesterol Edu-
cation Program (NCEP) guidelines for LDL-cholesterol
targets have changed [25]. Therefore, assessment of total
cholesterol provided the broadest applicability to our
entire cohort. Since our study included both patients
newly initiating treatment as well as those receiving ongo-
ing treatment, we chose to use the cholesterol measure-
ment at the end each patient's study period in order to
best capture a value that reflected the adherence period
observed. While other measurements for cholesterol, such
as averaging all measurements over the study period, may
have better captured the effect of adherence on cholesterol
levels for those with ongoing therapy, it would not have
been appropriate for those newly initiating therapy.
Finally, cholesterol level itself is a surrogate marker. We
did not attempt to obtain cardiovascular (CV) outcomes
for these patients, though recent data suggest that statin
adherence is associated with a significant reduction in CV
events and revascularization [17] and is therefore a valid
surrogate outcome marker.
Conclusion
This study demonstrates that providing patients with a
larger statin fill size is associated with greater adherence as
well as an increased likelihood of achieving lower choles-
terol levels. Though numerous factors contribute to both
statin adherence and cholesterol level, identifying an eas-
Table 3: Multivariate Predictors of Final Cholesterol Value (mg/dL)
Parameter Estimate (standard error) P Value
Intercept* 175.36 (2.78) <0.001
Age (per 10 year increase) -5.79 (0.77) <0.001
Female versus Male 12.60 (1.65) <0.001
Race (Hispanic versus White) -1.46 (1.97) 0.46
Race (Black versus White) -0.01 (2.44) 0.99
Race (Other versus White) 2.30 (3.38) 0.50
Mostly 30 Days Supply 3.20 (1.91) 0.09
<80% adherent 17.23 (1.64) <0.001
$0 Co-pay and uninsured -3.18 (2.14) 0.14
> $0 Co-pay and insured 3.01 (3.19) 0.35
> $0 Co-pay and uninsured 10.48 (3.09) <0.001
* Intercept is predicted cholesterol for a 50 year old white insured male with no co-payment, receiving mostly 60 day supply of statin medications, 
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ily modifiable factor related to both may be useful to cli-
nicians, pharmacies, and health care delivery systems.
Pharmacy and institutional policies that purposely limit
medication fill size to minimize medication wastage and
maximize co-payment collection may be shortsighted.
Further exploration of the policy and system changes nec-
essary to make dispensing larger prescription amounts
cost effective seems warranted.
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